Consider Buying These 2 Biotech Stocks Before 2023

NASDAQ: AMGN | Amgen Inc. News, Ratings, and Charts

AMGN – The biotech industry is expected to thrive amid the increasing medical requirements and greater investments in research and development. Moreover, investor sentiment toward biotech stocks has dramatically improved in recent months as the recession possibilities are rising. As this sector is known to provide a hedge against market downturns, investors might consider buying quality biotech stocks Amgen (AMGN) and Gilead Sciences (GILD). Keep reading….

The biotech industry thrived during the pandemic. Moreover, the United States spent the most on biotech research and development in 2020, totaling $88.42 billion. The industry is expected to remain in the limelight as global medical requirements continue to rise. According to Data Bridge Market Research, the biotechnology market is expected to grow at a CAGR of 29% from 2023 to 2030.

Historically, healthcare has outperformed during market downturns, providing a haven for those seeking stability for their portfolios. As recession fears are heightening, investors’ interest in biotech stocks is evident from the iShares Biotechnology ETF’s (IBB) 11.6% gains over three months and 11.3% gains over the past six months.

So, we believe investors might consider buying quality biotech stocks Amgen Inc. (AMGN - Get Rating) and Gilead Sciences, Inc. (GILD - Get Rating) to add a layer of protection to their portfolios.

Amgen Inc. (AMGN - Get Rating)

AMGN discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas.

On November 4, 2022, Robert A. Bradway, chairman and CEO, said, “Our medicines generated 8% volume growth in the quarter globally, with 11 products achieving record quarterly sales. This growth reflects the strong underlying demand for our medicines and the value they bring to patients.”

AMGN’s operating income came in at $2.66 billion for the third quarter that ended September 30, 2022, up 11.9% year-over-year. Moreover, the company’s net income came in at $2.14 billion, up 13.7% year-over-year. Also, its EPS came in at $3.98, up 20.2% year-over-year.

AMGN’s revenue is expected to increase 3.6% year-over-year to $27.19 billion in 2023. Its EPS is expected to increase 4.6% year-over-year to $18.47 in 2023. It surpassed EPS estimates in all each of the four trailing quarters. Over the past year, the stock has gained 15.6% to close the last trading session at $263.16. 

AMGN’s strong fundamentals are reflected in its POWR Ratings. The stock’s overall B rating equates to a Buy in our proprietary rating system. The POWR Ratings assess stocks by 118 different factors, each with its own weighting. 

AMGN has an A grade for Quality and a B grade for Stability. Within the Biotech industry, it is ranked #12 out of 375 stocks. Beyond what is stated above, we’ve also rated AMGN for Sentiment, Growth, Momentum, and Value. Get all the AMGN ratings here.

Gilead Sciences, Inc. (GILD - Get Rating)

Biopharmaceutical company GILD discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally for over three decades.

On December 27, GILD and Jounce Therapeutics, Inc. (JNCE) revised their current license agreement for GS-1811, allowing GILD to buy out any potential future contingent payments due under the license deal signed in August 2020. The GS-1811 announcement underscores GILD’s commitment to its fast-expanding oncology franchise and goal of delivering next-generation cancer medicines.

On December 22, Kite Pharma, Inc., a GILD Company, and Daiichi Sankyo Co., Ltd. (DSNKY) announced that the Japan Ministry of Health, Labour, and Welfare (MHLW) approved Yescarta, a chimeric antigen receptor (CAR) T-cell therapy, for the initial treatment of patients with relapsed/refractory large B-cell lymphoma.

GILD’s trodelvy’s sales came in at $180 million for the third quarter that ended September 30, 2022, up 78.2% year-over-year. The company’s current liabilities came in at $10.42 billion for the period ended September 30, 2022, compared to $11.61 billion for the period ended December 31, 2021.

Also, its total liabilities and equity came in at $62.56 billion, compared to $67.95 billion for the same period.

Street expects GILD’s EPS to increase 115.9% year-over-year to $1.49 for the quarter ending December 2022. It surpassed EPS estimates in three of the four trailing quarters. Over the past nine months, the stock has gained 40.8% to close the last trading session at $85.26.

GILD’s overall A rating equates to a Strong Buy in our POWR Ratings system. It has an A grade for Sentiment and a B for Value and Quality. It is ranked #3 in the same industry. We’ve also rated GILD for Momentum, Growth, and Stability. Get all GILD ratings here.

Want More Great Investing Ideas?

3 Stocks to DOUBLE This Year


AMGN shares were trading at $260.12 per share on Friday afternoon, down $3.04 (-1.16%). Year-to-date, AMGN has gained 19.28%, versus a -18.96% rise in the benchmark S&P 500 index during the same period.


About the Author: Rashmi Kumari


Rashmi is passionate about capital markets, wealth management, and financial regulatory issues, which led her to pursue a career as an investment analyst. With a master's degree in commerce, she aspires to make complex financial matters understandable for individual investors and help them make appropriate investment decisions. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
AMGNGet RatingGet RatingGet Rating
GILDGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


Investors Remain “Cautiously Optimistic”

The S&P 500 (SPY) has made great advances since the lows of early April. Yet seem to be stuck under resistance at 6,000. What happens next depends on tariff talks. So let’s talk about the latest news on that front.

Bull Market Til Proven Otherwise

The phrase that paid for investors in 2025 was “Bull market til proven otherwise” Steve Reitmeister explains why in his latest market update and preview of top stock picks.

Investor Alert: Mission Accomplished?

The S&P 500 (SPY) has broken out above the 200 day moving average. Does that mean that bear market fears are now over? And should investors be riding the bull to new heights? Read on for Steve Reitmeister’s answer...

Stock Market Update: It’s Complicated!

The S&P 500 (SPY) may have bounced 17% from recent lows, but the outlook for stocks from here is...in a word...COMPLICATED. Read on to get Steve Reitmeister full market outlook and trading plan for this complicated market environment.

Becoming More Bullish on Stocks, But...

Stocks are on a roll with the S&P 500 (SPY) up more than 10% from the recent lows. Before you start getting too giddy, you should read this updated market outlook and trading plan Steve Reitmeister.

Read More Stories

More Amgen Inc. (AMGN) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All AMGN News